Basal cell carcinoma (BCC) estimates for nearly 80% of non-melanoma skin cancers and is the most commonly diagnosed cancer globally. (1) The chief molecular driver in the development of BCC is abnormal Hedgehog pathway signaling, exhibited in >90% of BCCs cases. (2) Vismodegib is a first-in-class inhibitor of the Hedgehog signaling pathway. Vismode
4446 Reached
Black Lesion in Old Female
1974 Reached5 Comments11 Likes
Case of Increased Risk of Pregnancy-associated Breast Cancer Recurrence
1008 Reached2 Comments
Treatment of Recurrent Adult Medulloblastoma
2604 Reached1 Comments4 Likes
Management of Metastatic Prostate Cancer
1039 Reached5 Comments2 Likes
Shoulder Dislocation during Swimming
78 Reached9 Comments18 Likes